Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Amgen (NasdaqGS:AMGN) with a Neutral recommendation ...

Shares of Amgen (AMGN) added more than 3% in pre-market trading, rebounding from a 7.1% retreat in the previous ...

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

On Thursday, Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $321.91 which represents a slight increase of $0.12 or 0.04% from the prior close of $321.79. The stock opened at $322 and ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...